Skip to main content

Table 1 Ongoing and terminated active amyloid-beta immunotherapy clinical programs in Alzheimer’s disease

From: Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Name

Company

Phase

Antigen

Affitope AD02

Affiris/GlaxoSmithKline

2

Aβ1–6

CAD106

Novartis

2

Aβ1–6

Vanutide cridificar

Elan/Johnson & Johnson/Pfizer Inc.

2

Aβ1–6

ACI24

AC Immune/Bayer Healthcare Pharmaceuticals

1/2

Aβ1–15

V950

Merck & Co.

1

Not published

Affitope AD03

Affiris/GlaxoSmithKline

1

Pyroglutamate modified Aβ

UB311

United Biomedical

1

Aβ1–14

AN1792

Elan

Terminated

Aβ1–42

  1. Aβ, amyloid-beta.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193